［1］Siegel R，Ma J，Zou Z，et al.Cancer statistics，2014［J］.CA Cancer Clin，2014，64(1)：9-29.
[2]Amira B Kassem，Salem Eid Salem，Mohamed E Abdelrahim，et al.ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt［J］.Experimental and Molecular Pathology，2017，102(1)：78-85.
[3]Yang H，Li G，Li WF.Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer［J］.Genet Mol Res，2015，14(1)：700-705.
[4]Smith DH，Fiehn AM，Fogh L，et al.Measuring ERCC1 protein expression in cancer specimens：Validation of a novel antibody［J］.Sci Rep，2014，7(4)：4313.
[5]Van Huis-Tanja LH，Kweekel DM，Lu X，et al.Excision repair cross-complementation group 1 (ERCC1)C118T SNP does not affect cellular response to oxaliplatin［J］.Mutat Res，2014，759：37-44.
[6]Lord RV，Brabender J，Gandara D，et al.Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer［J］.Clin Cancer Res，2002，8(7)：2286-2291.
[7]Bellmunt J，Paz-Ares L，Cuello M，et al.Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy［J］.Ann Oncol，2007，18(3)：522-528.
[8]Kwon HC，Roh MS，Oh SY，et al.Prognostic value of expression of ERCC1，thymidylate synthase，and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer［J］.Ann Oncol，2007，18(3)：504-509.
[9]Li MX，Bi XY，Zhao H，et al.Excision repair cross-complementation group 1 is a prognostic biomarker in patients with colorectal cancer receiving chemotherapy［J］.Chin Med J (Engl)，2016，129(5)：586-593.
[10]Li S，Zhu L，Yao L，et al.Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU)adjuvant chemotherapy［J］.BMC Gastroenterol，2014，14：154-161.
[11]Lenz HJ，Lee FC，Yau L,et al.MAVERICC，a phase 2 study of mFOLFOX6-bevacizumab (BV)vs FOLFIRI-BV with biomarker stratification as first-line (1 L)chemotherapy (CT)in patients (pts)with metastatic colorectal cancer (mCRC)［J］.ASCO Annual Meeting Proceedings，2016，34：493.
[12]Li P，Fang YJ，Li F，et al.ERCC1，defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy［J］.Br J Cancer，2013，108(6)：1238-1244.
[13]Kelly H，Goldberg RM.Systemic therapy for metastatic colorectal cancer：Current options，current evidence［J］.J Clin Oncol，2005，23：4553-4560.
[14]Huang MY，Tsai HL，Lin CH，et al.Predictive value of ERCC1，ERCC2，and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy［J］.J Surg Oncol，2013，108(7)：457-464.
[15]Zhang Y，Ma J，Zhang S，et al.A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites［J］.Int J Colorectal Dis，2015，30(9)：1173-1183.
[16]Patel M，McSorley ST，Park JH，et al.The relationship between right-sided tumour location，tumour microenvironment，systemic inflammation，adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer［J］.Br J Cancer，2018，118(5)：705-712.
[17]Kornmann M，Staib L，Wiegel T，et al.Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer［J］.Clin Colorectal Cancer，2013，12(1)：54-61.
[18]Liang J，Jiang T，Yao RY，et al.The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer［J］.Cancer Chemother Pharmacol，2010，66(3)：493-500.
[19]Chiang JM，Hsieh PS，Chen JS，et al.Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy［J］.World J Surg Oncol，2014，12：197.
[20]Gao Y，Wang J，Zhou Y，et al.Evaluation of serum CEA，CA19-9，CA72-4，CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer［J］.Sci Rep，2018，8(1)：2732.